{"id":113599,"date":"2026-08-10T11:29:27","date_gmt":"2026-08-10T11:29:27","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/113599\/"},"modified":"2026-08-10T11:29:27","modified_gmt":"2026-08-10T11:29:27","slug":"chemometec-enters-collaboration-agreement-with-roche-diagnostics-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/113599\/","title":{"rendered":"ChemoMetec enters collaboration agreement with Roche Diagnostics"},"content":{"rendered":"<p>    <a href=\"https:\/\/s.yimg.com\/lo\/mysterio\/api\/FEF34E40DB22331C4363D02A1814AE82C5D6A4A4713F6D8FD955CAF8B3636837\/subgraphmysterio\/resizefit_w960;quality_80;format_webp\/https:%2F%2Fmedia.zenfs.com%2Fen%2Fglobe_newswire_uk_374%2Ffb7f647883e7e37b706ad984bdd29198\" target=\"_blank\" rel=\"noopener noreferrer nofollow\"><img loading=\"lazy\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"Chemometec A\/S\" height=\"87\" width=\"210\" class=\"yf-j98iil loader\"\/><\/a> Chemometec A\/S           <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">ANNOUNCEMENT NO. 311<\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">After entering a Letter of Intent with Roche Diagnostics in February 2026, aiming to pursue a collaboration with the goal of creating synergies between the parties&#8217; solutions in the field of bioprocess monitoring, ChemoMetec and Roche Diagnostics have today entered a collaboration agreement.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The agreement covers the development of a connection kit between the Roche-owned Cedex\u00ae Bio Analyzer and the ChemoMetec-owned Xcytomatic\u00ae 30 (XM30) cell counting analyzer, as well as aspects of the subsequent commercialization of the connectivity solution.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Roche will be responsible for the design of the connection kit and for the verification and validation activities. The connection kit is intended to result in a connectivity solution on hard- and software level, establishing a flawless integration and connection between the ChemoMetec XM30 and the Roche Cedex\u00ae Bio Analyzer.\u00a0\u00a0  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">The two parties commit to a joint go-to-market strategy to actively co-promote the combined solution to current and prospective customers, but each party will remain the sole seller of its respective instrument and analyzers.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Additional Information  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Martin Helbo Behrens, CEO<br \/>Tel.: (+45) 81 10 06 80  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">About ChemoMetec A\/S  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec&#8217;s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec&#8217;s customers include some of the world&#8217;s leading pharmaceutical companies.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For further information, go to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=res0mdDlclE-w6iGuPi2eiPxqtCeYvzgsvJ4_Qa5QRZUOLbv-5TJcTgzkamXgKH9qQiBCp6PTWZQXoOxen3-2B2yZu0EDHLONyXkj3zq6OY=\" data-ylk=\"slk:www.chemometec.com;elm:context_link;itc:0;sec:content-canvas;source:content-canvas%20default\" data-yga=\"{&quot;yLinkText&quot;:&quot;www.chemometec.com&quot;,&quot;yLinkElement&quot;:&quot;context_link&quot;,&quot;yModuleName&quot;:&quot;content-canvas&quot;,&quot;yTrafficOrigin&quot;:&quot;content-canvas default&quot;}\" target=\"_blank\" rel=\"noopener noreferrer nofollow\">www.chemometec.com<\/a>.  <\/p>\n<p class=\"text text-block paragraph text-left neo-font-paragraph-xl-reg  yf-18d6y07\" style=\"text-decoration: none; font-style: normal; text-transform: none; text-align: inherit; font-variant-numeric: normal;\">Attachment  <\/p>\n","protected":false},"excerpt":{"rendered":"Chemometec A\/S ANNOUNCEMENT NO. 311 After entering a Letter of Intent with Roche Diagnostics in February 2026, aiming&hellip;\n","protected":false},"author":2,"featured_media":113600,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[55299,2059,55301,55302,2058,134,2057],"class_list":["post-113599","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-chemometec","tag-collaboration","tag-connection-kit","tag-connectivity-solution","tag-letter-of-intent","tag-roche","tag-roche-diagnostics"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117070984809776239","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/113599","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=113599"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/113599\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/113600"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=113599"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=113599"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=113599"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}